Isoreserpine promotes beta-catenin degradation via Siah-1 up-regulation in HCT116 colon cancer cells

Biochem Biophys Res Commun. 2009 Sep 25;387(3):444-9. doi: 10.1016/j.bbrc.2009.07.027. Epub 2009 Jul 14.

Abstract

Aberrant accumulation of intracellular beta-catenin in intestinal epithelial cells is a frequent early event during the development of colon cancer. To identify small molecules that decrease the level of intracellular beta-catenin, we performed cell-based chemical screening using genetically engineered HEK293 reporter cells to detect compounds that inhibit TOPFlash reporter activity, which was stimulated by Wnt3a-conditioned medium. We found that isoreserpine promoted the degradation of intracellular beta-catenin by up-regulation of Siah-1 in HEK293 and HCT116 colon cancer cells. Moreover, isoreserpine repressed the expression of beta-catenin/T-cell factor (TCF)-dependent genes, such as cyclin D1 and c-myc, resulting in the suppression of HCT116 cell proliferation. Our findings suggest that isoreserpine can potentially be used as a chemotherapeutic agent against colon cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / isolation & purification
  • Antineoplastic Agents / pharmacology*
  • Gene Expression / drug effects
  • HCT116 Cells
  • Humans
  • Nuclear Proteins / metabolism*
  • Reserpine / chemistry
  • Reserpine / isolation & purification
  • Reserpine / pharmacology*
  • Stereoisomerism
  • Ubiquitin-Protein Ligases / metabolism*
  • Up-Regulation
  • Wnt Proteins / metabolism
  • beta Catenin / metabolism*

Substances

  • Antineoplastic Agents
  • CTNNB1 protein, human
  • Nuclear Proteins
  • Wnt Proteins
  • beta Catenin
  • Reserpine
  • Ubiquitin-Protein Ligases
  • seven in absentia proteins